Vaccine makers are seeing sales declines in the U.S. and upswings in Europe. Elsewhere, investors fretted over an AbbVie ...
Novo is threatening litigation in response to the move by the telehealth company to “unlawfully mass-market” what it called ...
The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is ...
Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...
Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...
In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13 ...
The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...
AstraZeneca’s investment will “span the value chain” of drug research and development and comes amid a prolonged surge in ...
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — ...
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results